8-K: Supernus Pharmaceuticals Q1 2026 Earnings Beat Expectations

Supernus Pharmaceuticals reports a strong first quarter 2026 with a 39% revenue increase driven by its four growth products, reiterating full-year guidance.

Summary

• Supernus Pharmaceuticals announced first quarter 2026 financial results, reporting total revenues of $207.7 million, a 39% increase year-over-year.
• Combined revenues from its four growth products (Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO) reached $149.1 million, a 56% increase compared to the same period last year.
• Net sales for Qelbree grew 20% to $77.9 million, and GOCOVRI sales increased 15% to $35.2 million.
• ONAPGO net product sales were $8.4 million, with a regulatory submission for a second supplier expected in Q3 2026.
• Collaboration revenue from ZURZUVAE was $27.6 million, with Biogen reporting a 100% increase in U.S. sales for the product.
• The company reported an operating loss of $8.3 million, an improvement from $10.3 million in Q1 2025.
• Adjusted operating earnings (non-GAAP) were $28.7 million, up from $25.9 million in the prior year.
• Net loss for the quarter was $2.3 million, or $0.04 per diluted share, an improvement from a net loss of $11.8 million, or $0.21 per diluted share, in Q1 2025.
• Cash, cash equivalents, and marketable securities stood at approximately $384.2 million as of March 31, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, improved profitability metrics, and reiteration of full-year guidance, indicating robust operational performance and positive market reception for key products.

Positives

• Total revenues increased by 39% to $207.7 million in Q1 2026 compared to Q1 2025.
• Revenues from the four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) increased by 56% to $149.1 million.
• Qelbree net sales grew 20% to $77.9 million, driven by volume.
• GOCOVRI net sales increased 15% to $35.2 million.
• ZURZUVAE collaboration revenue was $27.6 million, with Biogen reporting a 100% increase in U.S. sales.
• Operating loss decreased to $8.3 million from $10.3 million in the prior year.
• Adjusted operating earnings (non-GAAP) increased to $28.7 million from $25.9 million.
• Net loss improved significantly to $2.3 million from $11.8 million in the prior year.
• Cash, cash equivalents, and marketable securities increased to $384.2 million from $308.7 million.

Negatives

• Trokendi XR net sales decreased by 26% to $9.5 million.
• APOKYN net sales decreased by 48% to $7.7 million.
• Oxtellar XR net sales decreased by 27% to $7.4 million.
• Operating loss of $8.3 million was reported for the quarter.
• Net loss of $2.3 million was reported for the quarter.

Risks

• The company's ability to sustain and increase its profitability.
• The company's ability to raise sufficient capital to fully implement its corporate strategy.
• The company's future financial performance and projected expenditures.
• The company's ability to increase the number of prescriptions written for each of its products.
• The company's ability to increase its net revenue from its products.
• The company's ability to commercialize its products.
• The company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize product candidates.
• Risks and uncertainties associated with ordinary business operations and general economic conditions.

Future Outlook

The company reiterates its full year 2026 financial guidance, which includes projected total revenues of $840 - $870 million, combined R&D and SG&A expenses of $620 - $650 million, operating earnings of $0 - $30 million, and adjusted operating earnings (non-GAAP) of $140 - $170 million.

Management Comments

• "Our first quarter results reflect a strong start to the year, including a 56% year-over-year increase in combined revenues of our growth products," said Jack Khattar, President and CEO of Supernus.
• "We have positive momentum across our business, and I look forward to continued strong growth and execution of our key products throughout the year."

Industry Context

StockSavvy.ai notes that Supernus Pharmaceuticals' Q1 2026 results demonstrate continued growth in its CNS portfolio, particularly with its newer products like ZURZUVAE and ONAPGO contributing significantly. The strong performance of Qelbree and GOCOVRI further solidifies the company's position in its key therapeutic areas, while the decline in sales for older products like Trokendi XR and Oxtellar XR is expected as they face generic competition.

Comparison to Industry Standards

• The 39% year-over-year revenue growth for Supernus in Q1 2026 is significantly higher than the average revenue growth for mid-cap biopharmaceutical companies, which typically ranges from 10-20%.
• The 56% growth in combined revenues of its four key growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) outpaces the market growth for many CNS-specific drug categories.
• The improvement in net loss from $11.8 million to $2.3 million indicates a positive trend in profitability, moving towards breakeven or profitability, which is a key benchmark for sustainable growth in the pharmaceutical sector.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, increased revenue, and reduced net loss, with reiteration of full-year guidance.
• Employees: Potential for increased job security and opportunities due to company growth and positive momentum.
• Customers: Continued access to and potential for improved availability of CNS treatments like Qelbree and GOCOVRI.
• Suppliers: Increased demand for products may lead to greater business for suppliers of raw materials and manufacturing services.

Next Steps

• File a regulatory submission to the FDA for a second supplier for ONAPGO in the third quarter of 2026.
• Initiate a Phase 1 study for SPN-443 in adult healthy volunteers in the second half of 2026.
• Continue Phase 2b studies for SPN-817 and SPN-820.
• The webcast of the conference call will be archived on the company's website for 60 days.

Key Dates

Recommendation

The company delivered a strong Q1 2026 with significant revenue growth driven by its key products, improved profitability metrics, and reiterated full-year guidance. The positive momentum in its CNS portfolio, coupled with the pipeline progress, suggests continued upside potential, making it an attractive investment.

Keywords

Supernus Pharmaceuticals, 8-K, Q1 2026 Earnings, CNS Diseases, Qelbree, GOCOVRI, ZURZUVAE, ONAPGO